{
    "organizations": [],
    "uuid": "f9b7698d426645eeb954026a62fbd0aaa81a81de",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novan-provides-update-on-sb414-inf/brief-novan-provides-update-on-sb414-inflammatory-skin-disease-development-program-idUSASC0A29X",
    "ord_in_thread": 0,
    "title": "BRIEF-Novan Provides Update On SB414 Inflammatory Skin Disease Development Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Novan Inc:\n* NOVAN PROVIDES UPDATE ON SB414 INFLAMMATORY SKIN DISEASE DEVELOPMENT PROGRAM\n* NOVAN INC - SB414 - NITRIC OXIDE-RELEASING CREAM - SAFE AND WELL-TOLERATED IN PSORIASIS PHASE 1B TRIAL\n* NOVAN - ATOPIC DERMATITIS-PHASE 1B CLINICAL TRIAL FULLY ENROLLED, CO CONTINUES TO TARGET RECEIPT OF INITIAL TOPLINE RESULTS IN Q3 2018 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T20:14:00.000+03:00",
    "crawled": "2018-05-16T18:52:34.055+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novan",
        "inc",
        "novan",
        "provides",
        "update",
        "sb414",
        "inflammatory",
        "skin",
        "disease",
        "development",
        "program",
        "novan",
        "inc",
        "sb414",
        "nitric",
        "cream",
        "safe",
        "psoriasis",
        "phase",
        "1b",
        "trial",
        "novan",
        "atopic",
        "1b",
        "clinical",
        "trial",
        "fully",
        "enrolled",
        "co",
        "continues",
        "target",
        "receipt",
        "initial",
        "topline",
        "result",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}